The diabetes drug Semaglutide has been shown to be effective against obesity without causing adverse reactions.
Experts from Northwestern University in the United States have found that diabetic drug Semaglutide is an effective remedy for obesity.
The study included almost 2000 obese and non-diabetic people with an average weight of 105 kg.
One group of subjects was injected 2.4 mg of semaglutide weekly, and another group had a placebo. They also received individual consultations from nutritionists once a month to maintain a low-calorie diet and adequate level of physical activity.
- Some drugs having anti-inflammatory may prevent the worst effects of COVID-19 infection – says study
- COVID-19: Could a headache be the only symptom?
- Can Vaccines Fight Long-term COVID-19 Symptoms?
- “An incredible story of second chances”: Larry Miller confesses to murdering teen at age 16
- Elizabeth II gave up drinking
In 68 weeks, the first group lost about 15% of their body weight, while the second group lost only 2.4%. More than a third of participants who received Semaglutide lost more than 20% of their body weight.
Semaglutide activates the hormone glucagon-like peptide-1, which affects glucose concentration and appetite. It is prescribed to people with type 2 diabetes to better control blood sugar levels.
The study authors emphasized that the results obtained are significantly better than those of other anti-obesity drugs. Until recently, such successes could be achieved only with the help of surgery to reduce the stomach.
In addition, only a small number of participants experienced a common side effect of weight loss drugs – gastrointestinal problems.
The main problem for the widespread use of treatment at the moment is its cost – a monthly course of Semaglutide for diabetics costs almost $ 1000, and higher dosages are needed to lose weight. Given the drug’s effectiveness, there is a chance that insurance companies will start covering the costs of it.